



# Methylphenidate and Short-Term Cardiovascular Risk

Miguel Garcia-Argibay, PhD; Paul-Christian Bürkner, PhD; Paul Lichtenstein, PhD; Le Zhang, PhD; Brian M. D'Onofrio, PhD; Pontus Andell, MD, PhD; Zheng Chang, PhD; Samuele Cortese, MD, PhD; Henrik Larsson, PhD

## Abstract

**IMPORTANCE** There are concerns about the safety of medications for treatment of attention-deficit/hyperactivity disorder (ADHD), with mixed evidence on possible cardiovascular risk.

**OBJECTIVE** To assess whether short-term methylphenidate use is associated with risk of cardiovascular events.

**DESIGN, SETTING, AND PARTICIPANTS** This retrospective, population-based cohort study was based on national Swedish registry data. Participants were individuals with ADHD aged 12 to 60 years with dispensed prescriptions of methylphenidate between January 1, 2007, and June 30, 2012. Each person receiving methylphenidate (n = 26 710) was matched on birth date, sex, and county to up to 10 nonusers without ADHD (n = 225 672). Statistical analyses were performed from September 13, 2022, to May 16, 2023.

**MAIN OUTCOMES AND MEASURES** Rates of cardiovascular events, including ischemic heart disease, venous thromboembolism, heart failure, or tachyarrhythmias, 1 year before methylphenidate treatment and 6 months after treatment initiation were compared between individuals receiving methylphenidate and matched controls using a bayesian within-individual design. Analyses were stratified by history of cardiovascular events.

**RESULTS** The cohort included 252 382 individuals (15 442 [57.8% men]; median age, 20 (IQR, 15-31) years). The overall incidence of cardiovascular events was 1.51 per 10 000 person-weeks (95% highest density interval [HDI], 1.35-1.69) for individuals receiving methylphenidate and 0.77 (95% HDI, 0.73-0.82) for the matched controls. Individuals treated with methylphenidate had an 87% posterior probability of having a higher rate of cardiovascular events after treatment initiation (incidence rate ratio [IRR], 1.41; 95% HDI, 1.09-1.88) compared with matched controls (IRR, 1.18; 95% HDI, 1.02-1.37). The posterior probabilities were 70% for at least a 10% increased risk of cardiovascular events in individuals receiving methylphenidate vs 49% in matched controls. No difference was found in this risk between individuals with and without a history of cardiovascular disease (IRR, 1.11; 95% HDI, 0.58-2.13).

**CONCLUSIONS AND RELEVANCE** In this cohort study, individuals receiving methylphenidate had a small increased cardiovascular risk vs matched controls in the 6 months after treatment initiation. However, there was little evidence for an increased risk of 20% or higher and for differences in risk increase between people with and without a history of cardiovascular disease. Therefore, before treatment initiation, careful consideration of the risk-benefit trade-off of methylphenidate would be useful, regardless of cardiovascular history.

JAMA Network Open. 2024;7(3):e241349. doi:10.1001/jamanetworkopen.2024.1349

## Key Points

**Question** What is the cardiovascular risk associated with short-term methylphenidate use?

**Findings** In this cohort study of 252 382 individuals, methylphenidate-treated individuals showed a higher (10%) cardiovascular event rate compared with non-treated matched controls in the 6 months after treatment. However, there was no evidence for a more substantial difference ( $\geq 20\%$ ) or difference based on preexisting cardiovascular disease.

**Meaning** The findings of this study suggest that the small cardiovascular risk associated with short-term methylphenidate use should not be a reason to withhold treatment but suggest the need for individualized risk-benefit assessment and risk monitoring.

## + Supplemental content

Author affiliations and article information are listed at the end of this article.

## Introduction

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental condition affecting approximately 5% to 10% of school-aged children and 2% to 5% of adults.<sup>1</sup> Characterized by persistent and developmentally inappropriate inattention and/or hyperactivity/impulsivity, ADHD can co-occur with several mental and physical conditions,<sup>2-7</sup> including cardiovascular disease (CVD<sup>4</sup>), leading to a substantial burden on the health care system.<sup>8,9</sup>

Methylphenidate, a central nervous system stimulant, has long been used as a first-line medication for the treatment of ADHD. It has been shown to be efficacious in randomized clinical trials and useful in observational studies in decreasing ADHD symptom severity and related impairments.<sup>10</sup> However, despite its widespread use, there is still ongoing debate about the safety of methylphenidate. Among possible adverse effects, there is evidence showing small but statistically significant increases in blood pressure and heart rate following its use.<sup>11,12</sup> However, it is not clear whether and to what extent this increase in blood pressure is associated with an increased risk of cardiovascular conditions, as existing evidence is mixed. Some prospective and retrospective cohort studies have reported an increased risk of cardiovascular events in individuals receiving methylphenidate treatment.<sup>13-18</sup> In contrast, other retrospective, population-based cohort studies did not find any association between methylphenidate use and cardiovascular events.<sup>19-24</sup>

There are 2 crucial limitations in previous studies investigating the possible association between methylphenidate use and cardiovascular events. First, several studies did not adequately control unmeasured confounding factors that may lead to biased estimations.<sup>25-30</sup> A within-individual design, in which each individual serves as their own control, can address, at least partially, this methodologic limitation. Second, available studies based their conclusions on null hypothesis significance testing. While this is a widely used statistical method, it has several limitations.<sup>25,26</sup> Bayesian inference offers several advantages over null hypothesis significance testing,<sup>27-29</sup> and is often considered to be a more reliable and flexible method for statistical analysis.<sup>30</sup> Bayesian statistics, with its inherent capacity to express parameters and hypotheses as probabilities, offers clinicians an analytical framework with potential utility within the realm of medical practice. By encapsulating uncertainty through the lens of probabilities, Bayesian inference allows for a more comprehensive and nuanced understanding of clinical phenomena, facilitating informed decision-making and fostering personalized patient care.

We aimed to conduct what is, to our knowledge, the first Bayesian population-based self-controlled cohort study assessing the risk of cardiovascular adverse events 6 months after the start of methylphenidate treatment in individuals with ADHD with and without a history of CVD.

---

## Methods

The study was approved by the regional ethical review board in Stockholm, Sweden. The need for informed consent was waived because the study was register-based and data on the included individuals were deidentified. We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.<sup>31</sup>

### Study Design and Population

This study was based on the linkage of 3 population-based registers in Sweden via unique personal identity numbers<sup>32</sup>: the Total Population Register, the Prescribed Drug Register (PDR), and the National Patient Register (NPR). The Total Population Register includes data on birth, county, sex, death, and migration date. The PDR contains records of all prescribed drugs dispensed to the entire population of Sweden since 2005, with more than 99% national coverage. The NPR includes diagnosis codes and dates of both somatic and psychiatric inpatient care and outpatient specialist visits according to the *International Statistical Classification of Diseases and Related Health Problems, Tenth Revision* (ICD-10).

In this population-based study, we used a multilevel design—time nested within individuals—to compare the incidence of cardiovascular events within the same person (ie, each person served as their own control) between 2 periods: 12 months before (baseline) and 6 months after methylphenidate initiation (follow-up). By extending the baseline period to 12 months, we aimed to strengthen the precision of the estimated pretreatment event rate for each individual. This provides a more reliable basis for comparison when assessing the posttreatment change in event rate.

Furthermore, we compared the incidence of cardiovascular events in individuals with ADHD treated with methylphenidate and in controls with no history of ADHD or ADHD medication use. Individuals receiving methylphenidate were individually exact matched without replacement by birth date (month and year), sex, and county to up to 10 population-based controls. In matched controls, the date of methylphenidate initiation was set to be the same as their methylphenidate counterparts.

The study population included individuals with new use of methylphenidate aged between 12 and 60 years at the start of methylphenidate treatment. Individuals receiving methylphenidate were defined, in accordance with previous research,<sup>33</sup> as those who had a first dispensed methylphenidate prescription (Anatomical Therapeutic Chemical code N06BA04) between January 1, 2007, and June 30, 2012, as identified in the PDR. This definition includes those who had started methylphenidate treatment for the first time and those without any recorded prescription of methylphenidate for at least 1.5 years since the beginning of the PDR (July 1, 2005). Individuals were excluded from the study if they (1) received ADHD medications other than methylphenidate during the study period or did not have a diagnosis of ADHD in the NPR, (2) immigrated to Sweden after the start of period 1 (ie, 1 year before treatment initiation), or (3) died or emigrated before the end of period 2 (ie, 6 months after treatment initiation).

## Outcomes

Potential cardiovascular events were defined as those leading to any inpatient admission or outpatient attendance for ischemic heart disease (acute myocardial infarction or acute coronary syndrome), cerebrovascular disease (subarachnoid bleeding, hemorrhagic stroke, ischemic stroke, or other cerebrovascular disease), venous thromboembolism (deep vein thrombosis or pulmonary emboli), heart failure, or tachyarrhythmias (atrial fibrillation/flutter, supraventricular tachycardia, ventricular tachycardia, or cardiac arrest) until the end of the study period (December 31, 2013). eTable 1 in [Supplement 1](#) reports all *ICD-10* codes used for each diagnosis. Patients with at least 1 of the aforementioned diagnoses before the start of the follow-up period (ie, 1 year before treatment initiation) were considered to have a history of CVD.

## Statistical Analysis

A Bayesian multilevel negative binomial model with a random intercept for each individual was fitted to compare the incidence of cardiovascular events 1 year before methylphenidate initiation and after 6 months of methylphenidate treatment. In consecutive joint analyses, an interaction term was included between follow-up and the methylphenidate group vs the control group to assess whether there was any difference in the incidence of cardiovascular events between individuals receiving methylphenidate and matched controls in the follow-up compared with baseline. Analyses were further performed separately in persons with and without a history of CVD who were compared by including a 3-way interaction. All models were adjusted for mean-centered age at the start of methylphenidate treatment (confounder), and the log of person-weeks of baseline and follow-up were used as offset. Model parameters were estimated with the No-U-Turn Hamiltonian Monte Carlo sampling in Stan<sup>34</sup> (target average acceptance probability set to 0.97) using the r-package *brms*.<sup>35</sup> Additional information on priors, convergence assessment, and model fit can be found in the eMethods in [Supplement 1](#).

We estimated the posterior probabilities that the difference in the incidence rate for cardiovascular events between baseline and follow-up for individuals receiving methylphenidate and

matched controls (and the difference between them) exceeded a range of potential values (incidence rate ratio [IRR] >1.0, 1.1, 1.2, 1.3, and 1.4). Only individuals with at least 1 cardiovascular event during the selected 2 periods contributed to the analysis. Results are presented as IRR and median log rate with 95% highest density intervals (HDIs), and the region of practical equivalence (89% HDI region of practical equivalence [ROPE]: range ±0.1).<sup>30</sup> Data preparation was performed using SAS software, version 9.4 (SAS Institute Inc), and analyses were conducted using R, version 4.2.3.<sup>36</sup> Statistical analyses were performed from September 13, 2022, to May 16, 2023.

## Results

We identified 34 457 individuals who started methylphenidate treatment between January 1, 2007, and June 30, 2012. Among those, 369 individuals (1%) were excluded because of death (0.2%) and emigration or immigration (0.8%) during the study period, and 7378 (21.6%) were excluded due to not fulfilling the age criterion. Among 296 644 matched controls, 22 537 (7.6%) were excluded because of death (0.3%) and emigration or immigration during the study period (7.3%), and 48 435 (16.3%) due to age restrictions. A total of 252 382 individuals were included for analysis. Overall age was 20 (IQR, 15-31) years. The methylphenidate cohort included 26 710 individuals with a median age of 22 years (IQR, 16-34), including 11 268 (42.2%) females and 15 442 (57.8%) males. Among those receiving methylphenidate treatment, a history of cardiovascular events was reported in 383 (1.4%) individuals, and 187 (0.7%) participants had at least 1 cardiovascular event during the study period (**Table 1**). Among the matched controls, 1338 (0.6%) had a history of cardiovascular events and 631 (0.3%) had at least 1 cardiovascular event during the study period. The overall incidence of cardiovascular events was 1.51 per 10 000 person-weeks (95% HDI, 1.35-1.69) for the methylphenidate group and 0.77 (95% HDI, 0.73-0.82) for the matched controls. Among those with a history of CVD, the incidence was 42.18 (95% HDI, 35.16-50.08) per 10 000 person-weeks and, in those without a history of CVD, 0.92 (95% HDI, 0.80-1.06) events per 10 000 person-weeks. In the matched controls, the overall incidence was 56.54 (95% HDI, 52.05-61.24) in those with a history of CVD and, in those without a history of CVD, 0.44 (95% HDI, 0.41-0.47).

Model fit and convergence information can be found in the eResults, eTable 2, eFigure 1, and eFigure 2 in [Supplement 1](#). When comparing the incidence rate of cardiovascular events 1 year before methylphenidate initiation with 6 months after treatment (ie, baseline vs follow-up), we found an

**Table 1. Characteristics of the Study Population**

Variable	Group, No. (%)	
	Methylphenidate users (n = 26 710)	Matched controls (n = 225 672)
Sex		
Female	11 268 (42.2)	94 317 (41.8)
Male	15 442 (57.8)	131 355 (58.2)
History of CVD		
No	26 327 (98.6)	224 334 (99.4)
Yes	383 (1.4)	1338 (0.6)
Age at treatment initiation, median (IQR), y	22 (16-34)	20 (15-30)
Individuals with at least 1 cardiovascular event		
Baseline	110 (0.4)	395 (0.2)
Follow-up	77 (0.3)	273 (0.1)
No. of cardiovascular events (person-weeks)		
With history of CVD	123 (29 163)	576 (101 879)
Without history of CVD	185 (2 004 613)	755 (17 081 432)
Incidence rate (95% CI) per 10 000 person-weeks <sup>a</sup>		
Baseline	1.34 (1.16-1.55)	0.89 (0.84-0.95)
Follow-up	1.89 (1.58-2.26)	0.89 (0.81-0.97)


Abbreviation: CVD, cardiovascular disease.

<sup>a</sup> Baseline, 1 year before treatment initiation; follow-up, 6-month period after treatment initiation.

increased rate (IRR, 1.41; 95% HDI, 1.09-1.88; 0% in ROPE) with a 99% posterior probability for any difference in the rate between baseline and follow-up, 96% posterior probability for a difference larger than 10%, and 87% posterior probability for a difference larger than 20%. For the matched controls, we found an increased rate of cardiovascular events (IRR, 1.18; 95% HDI, 1.02-1.37; 14% in ROPE) with a 98% posterior probability for any difference, an 82% posterior probability for a difference larger than 10% (Figure 1), and a 40% probability for a difference larger than 20%. When comparing individuals receiving methylphenidate with matched controls, we found an 87% posterior probability for any difference in the IRR of cardiovascular events (IRR, 1.19; 95% HDI, 0.88-1.64), a 70% posterior probability for a difference larger than 10%, and a 49% posterior probability for a difference larger than 20% (Table 2). Figure 2 summarizes all posterior probabilities at different thresholds. The posterior probabilities decreased substantially for all risk differences equal to or greater than 20%.

In individuals without a history of CVD, we found a 70% posterior probability for a 10% difference in the rate of cardiovascular events between individuals receiving methylphenidate and matched controls (IRR, 1.23; 95% HDI, 0.84-1.87). In individuals with a history of CVD, we found a 65% posterior probability for any difference in the IRR of cardiovascular events between individuals

Figure 1. Posterior Distribution of the Log Rate for Methylphenidate Users and Matched Controls



Dashed lines represent the upper and lower bounds for the region of practical equivalence. Shaded areas contain the 95% highest density interval.

Table 2. Results From the Multilevel Negative Binomial Regression<sup>a</sup>

Variable and model	Median log rate	% in ROPE	IRR (95% HDI)	Posterior probability of IRR >specified threshold, %				
				1.0	1.1	1.2	1.3	1.4
<b>Overall</b>								
Methylphenidate: baseline vs follow-up	0.34	0	1.41 (1.09-1.88)	99	96	87	72	52
Controls, baseline vs follow-up	0.17	13.76	1.18 (1.02-1.37)	98	82	40	10	1
Methylphenidate vs controls	0.18	28.65	1.19 (0.88-1.64)	87	70	49	30	16
<b>No previous CVD</b>								
Methylphenidate: baseline vs follow-up	0.55	0	1.74 (1.24-2.42)	100	99	98	95	88
Controls: baseline vs follow-up	0.35	0	1.42 (1.15-1.72)	100	100	95	81	55
Methylphenidate vs controls	0.20	25.92	1.23 (0.84-1.87)	84	70	54	39	26
<b>Previous CVD</b>								
Methylphenidate: baseline vs follow-up	0.01	39	1.00 (0.65-1.54)	48	31	19	10	5
Controls: baseline vs follow-up	-0.10	50.17	0.90 (0.75-1.11)	17	3	0	0	0
Methylphenidate vs controls	0.09	33.77	1.09 (0.68-1.74)	65	49	35	24	15
<b>Difference</b>								
Previous CVD vs no history	0.11	24.90	1.11 (0.58-2.13)	62	50	36	23	11

Abbreviations: CVD, cardiovascular disease; HDI, highest density interval; IRR, incidence rate ratio; ROPE, region of practical equivalence. <sup>a</sup> Baseline was used as the reference category.

receiving methylphenidate and matched controls (IRR, 1.09; 95% HDI, 0.68-1.74), a 49% posterior probability for differences larger than 10%, and a 35% probability for differences larger than 20%. When comparing those with and without a history of CVD, we found a 62% probability that individuals receiving methylphenidate treatment without a history of CVD had a higher risk of cardiovascular events compared with those with a history (IRR, 1.11; 95% HDI, 0.58-2.13).


## Discussion

In this population-based cohort study of more than 250 000 children, adolescents, and adults, including 26 710 individuals receiving methylphenidate, we found evidence (87% posterior probability) of an increased rate of cardiovascular events associated with methylphenidate use after the first 6 months of pharmacologic treatment compared with matched controls, with inconclusive evidence regarding differences between those with vs without a history of CVD. When considering at least a 10% increased rate of cardiovascular events, the probability of finding a difference between individuals receiving methylphenidate and controls was lower (70%), and the probability decreased even further for larger differences in the rates of cardiovascular events.

In contrast with recent meta-analytic evidence from observational studies<sup>24</sup> showing no association between ADHD medication use and increased risk of CVD (relative risk, 1.22; 95% CI, 0.88-1.68), we found an increased cardiovascular risk with methylphenidate use. However, when quantifying this risk, we found little evidence for an increased risk of 20% or higher. We also found insufficient evidence for a difference in risk between individuals with and without a history of CVD. Our findings align with a Danish register-based study<sup>17</sup> reporting an elevated risk of CVD in individuals who started pharmacologic treatment for ADHD, as well as a lack of evidence supporting a difference in CVD risk between individuals with and without preexisting CVD. Furthermore, the increased IRR 1 year before the start of methylphenidate in the ADHD group aligns with recent studies suggesting that ADHD itself confers significantly greater cardiovascular risk.<sup>4</sup>

The somewhat higher risk in those without a history of CVD may be accounted for by the fact that individuals with a history of CVD are more closely monitored for cardiovascular risk factors and receive more intensive treatment to manage those risk factors. For instance, individuals with a history of CVD may be more likely to receive medications to manage hypertension, high low-density lipoprotein cholesterol levels, or diabetes, which are all risk factors for CVD. They may also be more likely to receive regular medical check-ups and undergo more frequent testing to monitor their CVD risk, ultimately reducing their recurrent event risk. In contrast, individuals without a history of CVD who are prescribed methylphenidate for ADHD may not receive the same level of monitoring and

Figure 2. Posterior Probabilities for Incidence Rate Ratio Between Methylphenidate Users and Matched Controls Using Different Thresholds





treatment for CVD risk factors. Therefore, they may be more vulnerable to the potential cardiovascular effects of methylphenidate use.

While the precise mechanisms by which methylphenidate could increase the risk of cardiovascular events remain elusive, it has been proposed that catecholamines may play an important role. Methylphenidate has been shown to increase catecholamine neurotransmission,<sup>37</sup> which in turn can activate cardiovascular  $\beta_1$  adrenoceptors<sup>38</sup> that might predispose to a range of cardiovascular events, including arrhythmias, myocardial infarction, and cardiac death. Furthermore, the sympathomimetic actions of methylphenidate could result in an increase in circulating norepinephrine levels, with attendant effects on peripheral vascular tone and vasoconstriction. Additionally, an increase in circulating catecholamine levels has been associated with a decrease in cardiac baroreflex sensitivity,<sup>39</sup> which could negatively affect the heart rate response to stress. The present study was not designed to investigate the mechanisms underlying the observed association between methylphenidate and cardiovascular events. Future studies need to replicate our results, ideally using approaches that avoid null hypothesis significance testing and control for confounding, to determine the safety cardiovascular profile of methylphenidate and identify the underlying mechanisms.

### Strengths and Limitations

Strengths of this study include the use of the PDR that allowed us to identify and include a large number of individuals receiving methylphenidate, with almost complete coverage (>99%) of dispensed prescription drugs in Sweden. Moreover, with the inclusion of diagnoses based on inpatient and outpatient medical records, we avoided faulty recollection of cardiovascular events. Furthermore, by using a within-individual approach, we compared the rate of cardiovascular events before and after methylphenidate treatment within the same individual (ie, each individual was their own control) adjusting for unmeasured constant factors. The variance of the individual-level residual addressed the influence of both measured and unmeasured sources. Additionally, to account for the possible effect of age rather than methylphenidate treatment, individuals with ADHD were matched by sex, birth date, and county, and age was included at the start of methylphenidate treatment as a between-level variable. As age was not a significant between-level predictor, it is unlikely that we introduced bias by using a 1-year baseline period.

Our findings should be interpreted considering some limitations. First, our data are observational rather than experimental, and thus causality cannot be inferred. Second, due to the lack of information on methylphenidate dose, we were unable to assess whether the cardiovascular risk varied as a function of the dose (eg, higher doses may be associated with an increased rate of cardiovascular events). Third, as with all register-based studies, we had no information on adherence. The number of days that a given filled prescription was supplied for does not necessarily represent the actual time of use, so that we could not rule out nonadherence. By using an intention-to-treat approach (ie, we assumed individuals used methylphenidate as prescribed), we might have potentially underestimated the associations. Fourth, as individuals older than 60 years were not included in this study, our conclusions derived from a restricted sample might not be extrapolated to broader population. Fifth, given that the Swedish PDR started in 2005, there were no records of prescriptions for ADHD before this date. As such, we only included individuals with new use of methylphenidate or those without any recorded prescription of methylphenidate for at least 1.5 years since the beginning of the PDR. It is possible that some individuals underwent and stopped methylphenidate treatment before 2005, exacerbating the susceptibility of cardiovascular events. This could potentially have inflated the association, assuming that methylphenidate is linked to an increased number of cardiovascular events.

There are several limitations to consider when generalizing the results of the current research findings on the association between methylphenidate and CVD to other countries, particularly those with different medical practices, national health care systems, and cultural factors than Sweden. The findings of this study were based on data collected from a Swedish population, which may not be

representative of other populations with varying demographic characteristics, lifestyles, and health behaviors. Medical practice and management of cardiovascular risk factors (eg, hypertension and hyperlipidemia) may also differ across countries, which could impact the generalizability of the results. Additionally, national health care systems, including access to health care services, prescription patterns, and drug regulations, can vary substantially between countries, potentially affecting the use and safety of methylphenidate. Moreover, cultural factors, such as attitudes toward medication use, patient preferences, and societal norms related to cardiovascular health and stimulant medications, may also vary across countries and influence the generalizability of the findings. Therefore, caution should be exercised when extrapolating the results of this study to other countries, and further research in diverse populations is warranted to better understand the generalizability of the observed association between methylphenidate and cardiovascular disease. In addition, although CVD misclassification cannot be completely ruled out, it is highly unlikely due to the nature and severity of CVD and the high positive predictive value from the NPR.<sup>40</sup>

---

## Conclusions

This cohort study found evidence supporting a small (10%) increased risk of cardiovascular events in individuals receiving methylphenidate compared with matched controls after 6 months of treatment. The probability of finding a difference in risk between users and nonusers decreased when considering risk of 20% or larger, with no evidence of differences between those with and without a CVD history. Overall, while the findings suggest the decision to initiate methylphenidate should incorporate considerations of potential adverse cardiovascular effects, they do not establish evidence of markedly elevated cardiovascular risk. Rather, they provide probabilistic evidence most consistent with a small increased rate of cardiovascular events attributable to methylphenidate exposure over 6 months that warrants consideration among the broader benefits and risks of treatment for individual patients.

---

## ARTICLE INFORMATION

**Accepted for Publication:** January 17, 2024.

**Published:** March 6, 2024. doi:10.1001/jamanetworkopen.2024.1349

**Open Access:** This is an open access article distributed under the terms of the [CC-BY License](#). © 2024 Garcia-Argibay M et al. *JAMA Network Open*.

**Corresponding Author:** Miguel Garcia-Argibay, PhD, School of Medical Sciences, Örebro University, SE-70182 Örebro, Sweden ([miguel.garcia-argibay@oru.se](mailto:miguel.garcia-argibay@oru.se)).

**Author Affiliations:** School of Medical Sciences, Örebro University, Faculty of Medicine and Health, Örebro, Sweden (Garcia-Argibay, Larsson); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Garcia-Argibay, Lichtenstein, Zhang, D'Onofrio, Chang, Larsson); Cluster of Excellence SimTech, University of Stuttgart, Stuttgart, Germany (Bürkner); The Department of Psychological and Brain Sciences at Indiana University, Bloomington (D'Onofrio); Unit of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden (Andell); Heart and Vascular Division, Karolinska University Hospital, Stockholm, Sweden (Andell); School of Psychology, University of Southampton, Southampton, United Kingdom (Cortese); Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, United Kingdom (Cortese); Solent NHS Trust, Southampton, United Kingdom (Cortese); Hassenfeld Children's Hospital at NYU Langone, New York University Child Study Center, New York City (Cortese); DiMePRE-J-Department of Precision and Regenerative Medicine-Jonic Area, University of Bari Aldo Moro, Bari, Italy (Cortese).

**Author Contributions:** Dr Garcia-Argibay had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Cortese and Larsson contributed equally to the study.

**Concept and design:** Garcia-Argibay, Larsson.



*Acquisition, analysis, or interpretation of data:* Garcia-Argibay, Bürkner, Lichtenstein, Zhang, D'Onofrio, Andell, Chang, Cortese.

*Drafting of the manuscript:* Garcia-Argibay.

*Critical review of the manuscript for important intellectual content:* All authors.

*Statistical analysis:* Garcia-Argibay, Bürkner.

*Obtained funding:* D'Onofrio, Larsson.

*Administrative, technical, or material support:* Garcia-Argibay, Lichtenstein, Zhang, Chang.

*Supervision:* Bürkner, Andell, Cortese, Larsson.

**Conflict of Interest Disclosures:** Dr Cortese reported receiving personal fees from the Association for Child and Adolescent Mental Health, British Association of Psychopharmacology, and Canadian ADHD Resource Alliance outside the submitted work. Dr Larsson reported receiving grants from Shire/Takeda and personal fees from Shire/Takeda, Evolan, and Medici outside the submitted work. No other disclosures were reported.

**Funding/Support:** The project received funding from the European Union's Horizon 2020 research and innovation program under grant agreement 965381 and the Swedish Research Council for Health, Working Life, and Welfare (2019-01172). Dr Larsson acknowledges receiving financial support from the Swedish Research Council (2018-02599) and the Swedish Brain Foundation (FO2021-0115).

**Role of the Funder/Sponsor:** The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Disclaimer:** This report reflects only the author's view, and the European Union is not responsible for any use that may be made of the information it contains.

**Data Sharing Statement:** See [Supplement 2](#).

## REFERENCES

- Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. *Int J Epidemiol*. 2014;43(2):434-442. doi:10.1093/ije/dyt261
- Faraone SV, Banaschewski T, Coghill D, et al. The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. *Neurosci Biobehav Rev*. 2021;128:789-818. doi:10.1016/j.neubiorev.2021.01.022
- Garcia-Argibay M, du Rietz E, Lu Y, et al. The role of ADHD genetic risk in mid-to-late life somatic health conditions. *Transl Psychiatry*. 2022;12(1):152. doi:10.1038/s41398-022-01919-9
- Li L, Yao H, Zhang L, et al. Attention-deficit/hyperactivity disorder is associated with increased risk of cardiovascular diseases: a systematic review and meta-analysis. *JCPP Adv*. 2023;3(3):e12158. doi:10.1002/jcv2.12158
- Garcia-Argibay M, Du Rietz E, Hartman CA, et al. Cardiovascular risk factors in attention-deficit/hyperactivity disorder: a family design study of Swedish conscripts. *Int J Methods Psychiatr Res*. 2022;31(4):e1930. doi:10.1002/mpr.1930
- Dobrosavljevic M, Zhang L, Garcia-Argibay M, et al. Attention-deficit/hyperactivity disorder as a risk factor for dementia and mild cognitive impairment: a population-based register study. *Eur Psychiatry*. 2021;65(1):1-19.
- Garcia-Argibay M, Li L, Du Rietz E, et al. The association between type 2 diabetes and attention-deficit/hyperactivity disorder: a systematic review, meta-analysis, and population-based sibling study. *Neurosci Biobehav Rev*. 2023;147:105076. doi:10.1016/j.neubiorev.2023.105076
- Biederman J, Monuteaux MC, Mick E, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. *Psychol Med*. 2006;36(2):167-179. doi:10.1017/S0033291705006410
- Garcia-Argibay M, Pandya E, Ahnemark E, et al. Healthcare utilization and costs of psychiatric and somatic comorbidities associated with newly diagnosed adult ADHD. *Acta Psychiatr Scand*. 2021;144(1):50-59. doi:10.1111/acps.13297
- Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. *Lancet Psychiatry*. 2018;5(9):727-738. doi:10.1016/S2215-0366(18)30269-4
- Hennissen L, Bakker MJ, Banaschewski T, et al; ADDUCE consortium. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. *CNS Drugs*. 2017;31(3):199-215. doi:10.1007/s40263-017-0410-7

12. Mick E, McManus DD, Goldberg RJ. Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults. *Eur Neuropsychopharmacol*. 2013;23(6):534-541. doi:10.1016/j.euroneuro.2012.06.011
13. McCarthy S, Cranswick N, Potts L, Taylor E, Wong ICK. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. *Drug Saf*. 2009;32(11):1089-1096. doi:10.2165/11317630-000000000-00000
14. Schelleman H, Bilker WB, Kimmel SE, et al. Methylphenidate and risk of serious cardiovascular events in adults. *Am J Psychiatry*. 2012;169(2):178-185. doi:10.1176/appi.ajp.2011.11010125
15. Dalsgaard S, Kvist AP, Leckman JF, Nielsen HS, Simonsen M. Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study. *J Child Adolesc Psychopharmacol*. 2014;24(6):302-310. doi:10.1089/cap.2014.0020
16. Shin JY, Roughead EE, Park BJ, Pratt NL. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. *BMJ*. 2016;353:i2550. doi:10.1136/bmj.i2550
17. Eroglu TE, Halili A, Arulmuruganthavadevel A, et al. Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study. *Eur Heart J Cardiovasc Pharmacother*. 2023;9(7):658-665. doi:10.1093/ehjcvp/pvad028
18. Zhang L, Li L, Andell P, et al. Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases. *JAMA Psychiatry*. Published online November 22, 2023. doi:10.1001/jamapsychiatry.2023.4294
19. Schelleman H, Bilker WB, Strom BL, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. *Pediatrics*. 2011;127(6):1102-1110. doi:10.1542/peds.2010-3371
20. Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. *N Engl J Med*. 2011;365(20):1896-1904. doi:10.1056/NEJMoa1110212
21. Winterstein AG, Gerhard T, Kubilis P, et al. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. *BMJ*. 2012;345:e4627. doi:10.1136/bmj.e4627
22. Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. *Pediatrics*. 2007;120(6):e1494-e1501. doi:10.1542/peds.2007-0675
23. Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. *JAMA*. 2011;306(24):2673-2683. doi:10.1001/jama.2011.1830
24. Zhang L, Yao H, Li L, et al. Risk of cardiovascular diseases associated with medications used in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. *JAMA Netw Open*. 2022;5(11):e2243597. doi:10.1001/jamanetworkopen.2022.43597
25. Marden JI. Hypothesis testing: from P values to Bayes factors. *J Am Stat Assoc*. 2000;95(452):1316. doi:10.2307/2669779
26. Szucs D, Ioannidis JPA. When null hypothesis significance testing is unsuitable for research: a reassessment. *Front Hum Neurosci*. 2017;11:390. doi:10.3389/fnhum.2017.00390
27. Quintana DS, Williams DR. Bayesian alternatives for common null-hypothesis significance tests in psychiatry: a non-technical guide using JASP. *BMC Psychiatry*. 2018;18(1):178. doi:10.1186/s12888-018-1761-4
28. Wagenmakers EJ, Marsman M, Jamil T, et al. Bayesian inference for psychology. part I: theoretical advantages and practical ramifications. *Psychon Bull Rev*. 2018;25(1):35-57. doi:10.3758/s13423-017-1343-3
29. Dunson DB. Commentary: practical advantages of bayesian analysis of epidemiologic data. *Am J Epidemiol*. 2001;153(12):1222-1226. doi:10.1093/aje/153.12.1222
30. McElreath R. *Statistical Rethinking: A Bayesian Course With Examples in R and Stan*. Chapman & Hall/CRC; 2018. doi:10.1201/9781315372495
31. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med*. 2007;147(8):573-577. doi:10.7326/0003-4819-147-8-200710160-00010
32. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekblom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. *Eur J Epidemiol*. 2009;24(11):659-667. doi:10.1007/s10654-009-9350-y

33. Hollis C, Chen Q, Chang Z, et al. Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study. *Lancet Psychiatry*. 2019;6(8):651-658. doi:10.1016/S2215-0366(19)30189-0
34. Carpenter B, Gelman A, Hoffman MD, et al. Stan: a probabilistic programming language. *J Stat Softw*. 2017; 76(1):1. doi:10.18637/jss.v076.i01
35. Bürkner PC. Advanced bayesian multilevel modeling with the R Package brms. *R J*. 2018;10(1):395. doi:10.32614/RJ-2018-017
36. R Development Core Team. R: a language and environment for statistical computing. 2020. Accessed November 13, 2022. <http://www.R-project.org>
37. Berridge CW, Devilbiss DM, Andrzejewski ME, et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. *Biol Psychiatry*. 2006;60(10):1111-1120. doi:10.1016/j.biopsych.2006.04.022
38. Motiejunaite J, Amar L, Vidal-Petiot E. Adrenergic receptors and cardiovascular effects of catecholamines. *Ann Endocrinol (Paris)*. 2021;82(3-4):193-197. doi:10.1016/j.ando.2020.03.012
39. Adlan AM, Paton JFR, Lip GYH, Kitas GD, Fisher JP. Increased sympathetic nerve activity and reduced cardiac baroreflex sensitivity in rheumatoid arthritis. *J Physiol*. 2017;595(3):967-981. doi:10.1113/JP272944
40. Ludvigsson JF, Andersson E, Ekblom A, et al. External review and validation of the Swedish national inpatient register. *BMC Public Health*. 2011;11(1):450. doi:10.1186/1471-2458-11-450

#### SUPPLEMENT 1.

**eMethods.** Bayesian Statistics and Detailed Methods

**eResults.** Detailed Results

**eTable 1.** Diagnoses and ICD-10 Codes to Define the Occurrence of Short-Term Cardiovascular Events

**eTable 2.** Model Fit Comparison Among Negative Binomial, Poisson, Zero-Inflated Poisson, and Zero-Inflated Negative Binomial

**eFigure 1.** Trace Plot of the Four MCMC Chains After Burn-In

**eFigure 2.** Graphical Posterior Predictive Checking Using an Overlay of Density Plots and Distribution of Mean Values in MPH Users and Matched Controls Based on 300 Posterior Draws

**eReferences**

#### SUPPLEMENT 2.

**Data Sharing Statement**